Baudax Bio Reports Second Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- Lula, Brazil's iconic working class president, wins historic fourth term in dramatic comeback
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
- Accenture shares fall on insider sales and analyst downgrade
- Wall Street closes lower to end rocky week
- Credo Technology shares fall on competition concerns
Baudax Bio (BXRX) Misses Q2 EPS by $1.07
August 10, 2020 7:18 AM EDTBaudax Bio (NASDAQ: BXRX) reported Q2 EPS of ($1.72), $1.07 worse than the analyst estimate of ($0.65).
The second quarter of 2020 was most important because of the full commercial launch of ANJESO, said Gerri Henwood, President and Chief Executive Officer of Baudax Bio. We believe that with... More



